EXCLUSIVE EWTX 350% BUY/HOLD techs/fundies with catalyst
🔸Let's review EWTX daily price chart. Strong V-shape recovery in progress. YTD gains at 218% off the lows, which is an EXCELLENT indicator of the overall health of the stock. Trading 5% below 52 week high.
🔸Based on technicals, I envision a C*H breakout in 2025 after we hit overhead resistance we can expect a pullback in order to fill the massive liquidity gap left behind near 22 USD. currently stock is trading near 35 handle and expecting limited upside going forward into Q4 2024. Market cap is hovering near 3 Bln USD
so it's not a penny stock and also market cap is not inflated.
🔸CYTK competitor stock chart on the right, similarly priced and also same line of business as EWTX. Trading at 53 USD now previously maxed out at 100 USD, current CYTK market cap is 6 Bln USD, at the peak market cap was 12 Bln USD. So potentially EWTX can do x4 from current levels in order to hit CYTK max market cap. this means x4 stock prices for EWTX from current levels, so it's 34 x 4 = 136 USD max projected stock price.
🔸My PT for EWTX in 2025 is 100 USD, based on the technicals and fundamentals. Recommended strategy bulls: wait for pullback/rejection from overhead resistance and be ready to BUY/HOLD once we do a COMPLETE gap fill of the liquidity gap near 22 USD. Target is 100 USD, 350%+ upside from entry price. Good luck traders!
🔸Below supplementary fundies info on EWTX / some info on the positive catalysts, you can dig deeper if required.
🔸Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious muscle diseases, particularly rare neuromuscular and cardiac disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company leverages its deep expertise in muscle biology to create innovative therapies aimed at unmet medical needs.
🔸Their lead product candidate, EDG-5506, is being developed to treat Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). This small molecule is designed to prevent contraction-induced muscle damage, offering potential benefits in improving muscle function for patients with ystrophinopathies. The drug is currently in Phase 2 trials, and has shown promising results in reducing muscle damage biomarkers
🔸Another key program focuses on EDG-7500, an experimental therapy for hypertrophic cardiomyopathy (HCM). This drug is a selective sarcomere modulator designed to improve cardiac relaxation and contraction. The company initiated Phase 1 trials for EDG-7500 in 2023.
🔸Edgewise is dedicated to both advancing scientific research and engaging with patient communities, frequently collaborating with organizations such as the Muscular Dystrophy Association and the Parent Project Muscular Dystrophy
🔸The biotech company tested its drug, EDG-7500, in healthy volunteers and patients with obstructive hypertrophic cardiomyopathy. In this disease, a genetic mutation causes the heart ventricles to thicken. This limits cardiac function and exercise capacity.
🔸After a single dose, patients showed improved blood flow from the left ventricle. But sometimes drugs can do their job too well, suppressing cardiac function — a measure known as reduced left ventricular ejection fraction, or LVEF. But patients didn't show meaningful reductions in LVEF.
🎁Please hit the like button and
🎁Leave a comment to support our team!
RISK DISCLAIMER:
Trading Futures , Forex, CFDs and Stocks involves a risk of loss.
Please consider carefully if such trading is appropriate for you.
Past performance is not indicative of future results.
Always limit your leverage and use tight stop loss.
🔸Based on technicals, I envision a C*H breakout in 2025 after we hit overhead resistance we can expect a pullback in order to fill the massive liquidity gap left behind near 22 USD. currently stock is trading near 35 handle and expecting limited upside going forward into Q4 2024. Market cap is hovering near 3 Bln USD
so it's not a penny stock and also market cap is not inflated.
🔸CYTK competitor stock chart on the right, similarly priced and also same line of business as EWTX. Trading at 53 USD now previously maxed out at 100 USD, current CYTK market cap is 6 Bln USD, at the peak market cap was 12 Bln USD. So potentially EWTX can do x4 from current levels in order to hit CYTK max market cap. this means x4 stock prices for EWTX from current levels, so it's 34 x 4 = 136 USD max projected stock price.
🔸My PT for EWTX in 2025 is 100 USD, based on the technicals and fundamentals. Recommended strategy bulls: wait for pullback/rejection from overhead resistance and be ready to BUY/HOLD once we do a COMPLETE gap fill of the liquidity gap near 22 USD. Target is 100 USD, 350%+ upside from entry price. Good luck traders!
🔸Below supplementary fundies info on EWTX / some info on the positive catalysts, you can dig deeper if required.
🔸Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious muscle diseases, particularly rare neuromuscular and cardiac disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company leverages its deep expertise in muscle biology to create innovative therapies aimed at unmet medical needs.
🔸Their lead product candidate, EDG-5506, is being developed to treat Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). This small molecule is designed to prevent contraction-induced muscle damage, offering potential benefits in improving muscle function for patients with ystrophinopathies. The drug is currently in Phase 2 trials, and has shown promising results in reducing muscle damage biomarkers
🔸Another key program focuses on EDG-7500, an experimental therapy for hypertrophic cardiomyopathy (HCM). This drug is a selective sarcomere modulator designed to improve cardiac relaxation and contraction. The company initiated Phase 1 trials for EDG-7500 in 2023.
🔸Edgewise is dedicated to both advancing scientific research and engaging with patient communities, frequently collaborating with organizations such as the Muscular Dystrophy Association and the Parent Project Muscular Dystrophy
🔸The biotech company tested its drug, EDG-7500, in healthy volunteers and patients with obstructive hypertrophic cardiomyopathy. In this disease, a genetic mutation causes the heart ventricles to thicken. This limits cardiac function and exercise capacity.
🔸After a single dose, patients showed improved blood flow from the left ventricle. But sometimes drugs can do their job too well, suppressing cardiac function — a measure known as reduced left ventricular ejection fraction, or LVEF. But patients didn't show meaningful reductions in LVEF.
🎁Please hit the like button and
🎁Leave a comment to support our team!
RISK DISCLAIMER:
Trading Futures , Forex, CFDs and Stocks involves a risk of loss.
Please consider carefully if such trading is appropriate for you.
Past performance is not indicative of future results.
Always limit your leverage and use tight stop loss.
評論
Getting Started with Forex Prop Trading: Intro Guide
評論
Replace a 100 000 USD salary with income from trading
評論
評論
評論
this is a swing trade setup for patient and intelligent traders
not going to work for meme coin degens
評論
💎all my links on one page
taplink.cc/prsyndicate
🔥primary telegram channel
t.me/thesyndicate001
🚀75%+ win rate free gold signals
t.me/syndicategold001
🏧MT4 Forex EA/bot 5%/day AI algo trading
breakoutedge.cc/
taplink.cc/prsyndicate
🔥primary telegram channel
t.me/thesyndicate001
🚀75%+ win rate free gold signals
t.me/syndicategold001
🏧MT4 Forex EA/bot 5%/day AI algo trading
breakoutedge.cc/
相關出版品
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。